<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054075</url>
  </required_header>
  <id_info>
    <org_study_id>BivalveSarsCov-Protocol</org_study_id>
    <secondary_id>PPA nº 117380</secondary_id>
    <nct_id>NCT05054075</nct_id>
  </id_info>
  <brief_title>Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19</brief_title>
  <official_title>Methodological Design for Evaluating the Immune Capacity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Human Infection: Intelligent Medicine Integration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Porto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Politécnico de Bragança</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade do Porto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present work proposes to find if a bio-active composite in the hemolymph or plasma of the&#xD;
      freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating&#xD;
      the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in&#xD;
      silico procedures using organic fluids from 54 bivalves (in very specific conditions) to&#xD;
      evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an&#xD;
      integrative diagnosis by a computational Mora®Nova apparatus to access the basal and&#xD;
      experimental human physiological parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A deep and consistent study will be developed with an increase in the human sampling for&#xD;
      better understanding the intervention efficacy of this intelligence medicine integrator, the&#xD;
      Mora® Nova method. These in silico experiments when associated with the bioresonance&#xD;
      frequencies from stimulated hemolymph compounds of the freshwater bivalve A. cygnea, may lead&#xD;
      us to expect high plasticity and immunological potential.&#xD;
&#xD;
      Obviously, additional in vitro studies in future, with adequate culture cell lineages in&#xD;
      different conditions and with bioresonance treatment by Mora® Nova method, should also be&#xD;
      accomplished with hemolymph/plasma interference to confirm the pertinence, and the real&#xD;
      efficacy on SARS / COVID-19 infection as well as to clarify the respective biological&#xD;
      mechanisms.&#xD;
&#xD;
      In addition, to analyze and evaluate any specific bioactive compound from the induced&#xD;
      hemolymph condition needs molecular experiments which can give deep structural information&#xD;
      concerning any efficient molecule against the SARS / COVID-19 virus lineage and respective&#xD;
      mutants. Effectively, according to current scientific opinion, the virus mutation phenomenon&#xD;
      leads to great and problematic difficulty for maintaining the collective and human global&#xD;
      immunization. In this case, the present Mora methodology offers a very functional, dynamic,&#xD;
      and efficient process when combined with a biological model, as the bivalve A. cygnea, with&#xD;
      high plasticity and eventual molecular reconstructive adaptation. This Mora procedure can&#xD;
      extend to other immune-depressive diseases namely cancer, rheumatoid arthritis, and&#xD;
      neurodegenerative diseases combining with respective stimulated bivalve fluids. It suggests&#xD;
      opening a promising future perspective when applied to large human sampling as well as with&#xD;
      in vitro cellular assays.&#xD;
&#xD;
      In addition, to explore this research with in vitro cell cultures and to do the&#xD;
      characterization and the effects from bio-compounds on similar diseases is our close&#xD;
      objective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary system</measure>
    <time_frame>T0 - Day 1 - Baseline</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary system change</measure>
    <time_frame>T1 - Day 1 - After in silico human virus infestation</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary system change</measure>
    <time_frame>T2 - Day 1 - After adding the interface of the original fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary system change</measure>
    <time_frame>T3 - Day 1 - After adding the interface of virus impregnated fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary system change</measure>
    <time_frame>T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on pulmonary system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac system</measure>
    <time_frame>T0 - Day 1 - Baseline</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac system change</measure>
    <time_frame>T1 - Day 1 - After in silico human virus infestation</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac system change</measure>
    <time_frame>T2 - Day 1 - After adding the interface of the original fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac system change</measure>
    <time_frame>T3 - Day 1 - After adding the interface of virus impregnated fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac system change</measure>
    <time_frame>T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on cardiac system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic system</measure>
    <time_frame>T0 - Day 1 - Baseline</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic system change</measure>
    <time_frame>T1 - Day 1 - After in silico human virus infestation</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic system change</measure>
    <time_frame>T2 - Day 1 - After adding the interface of the original fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic system change</measure>
    <time_frame>T3 - Day 1 - After adding the interface of virus impregnated fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic system change</measure>
    <time_frame>T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on immunologic system biopoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal system</measure>
    <time_frame>T0 - Day 1 - Baseline</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal system Change</measure>
    <time_frame>T1 - Day 1 - After in silico human virus infestation</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal system Change</measure>
    <time_frame>T2 - Day 1 - After adding the interface of the original fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal system Change</measure>
    <time_frame>T3 - Day 1 - After adding the interface of virus impregnated fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal system Change</measure>
    <time_frame>T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on gastrointestinal system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nervous system</measure>
    <time_frame>T0 - Day 1 - Baseline</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on nervous system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nervous system change</measure>
    <time_frame>T1 - Day 1 - After in silico human virus infestation</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on nervous system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nervous system change</measure>
    <time_frame>T2 - Day 1 - After adding the interface of the original fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on nervous system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nervous system change</measure>
    <time_frame>T3 - Day 1 - After adding the interface of virus impregnated fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on nervous system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nervous system change</measure>
    <time_frame>T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on nervous system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine system</measure>
    <time_frame>T0 - Day 1 - Baseline</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine system change</measure>
    <time_frame>T1 - Day 1 - After in silico human virus infestation</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine system change</measure>
    <time_frame>T2 - Day 1 - After adding the interface of the original fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine system change</measure>
    <time_frame>T3 - Day 1 - After adding the interface of virus impregnated fluid</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine system change</measure>
    <time_frame>T4 - Day 3 - After adding the interface of virus incubated fluid during 48 hours</time_frame>
    <description>Voll Electromagnetic conductance reading (Hz) on endocrine system biopoints</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronavirus Infections</condition>
  <condition>Coronavirus Sars-Associated</condition>
  <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Vaccinated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects that received a vaccine against COVID-19 lineage virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-vaccinated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects that did not receive a vaccine against COVID-19 lineage virus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects that are infected with a COVID-19 lineage virus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Marine liquid and fluids</intervention_name>
    <description>Marine liquid and fluids extracted from freshwater bivalve of A. cygnea (under very specific conditions)</description>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_label>Non-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Impregnation</intervention_name>
    <description>SARS / COVID-19 fluid/liquid - impregnation</description>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_label>Non-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Incubation</intervention_name>
    <description>SARS / COVID-19 fluid-bivalve-incubation</description>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_label>Non-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Manipulation</intervention_name>
    <description>Bivalve Manipulation - Stress inducing</description>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_label>Non-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Refrigeration</intervention_name>
    <description>Refrigerated fluid to check for maintained response</description>
    <arm_group_label>Infected</arm_group_label>
    <arm_group_label>Non-vaccinated</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with normal physiological state or any kind of comorbidity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects in highly critical health state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge P Machado, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ICBAS - Instituto de Ciências Biomédicas Abel Salazar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge P Machado, PhD</last_name>
    <phone>+351917670878</phone>
    <email>jmachado@icbas.up.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lara Lopes</last_name>
    <phone>+351938532115</phone>
    <email>llpsique@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Politécnico de Bragança</name>
      <address>
        <city>Bragança</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICBAS - University of Porto</name>
      <address>
        <city>Porto</city>
        <zip>4050-313</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Antunes F, Hinzmann M, Lopes-Lima M, Machado J, Martins da Costa P. Association between environmental microbiota and indigenous bacteria found in hemolymph, extrapallial fluid and mucus of Anodonta cygnea (Linnaeus, 1758). Microb Ecol. 2010 Aug;60(2):304-9. doi: 10.1007/s00248-010-9649-y. Epub 2010 Mar 27.</citation>
    <PMID>20349058</PMID>
  </reference>
  <reference>
    <citation>Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Lin M, Tan N, Linster M, Chia WN, Chen MI, Wang LF, Ooi EE, Kalimuddin S, Tambyah PA, Low JG, Tan YJ, Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020 Aug;584(7821):457-462. doi: 10.1038/s41586-020-2550-z. Epub 2020 Jul 15.</citation>
    <PMID>32668444</PMID>
  </reference>
  <reference>
    <citation>Allam B, Raftos D. Immune responses to infectious diseases in bivalves. J Invertebr Pathol. 2015 Oct;131:121-36. doi: 10.1016/j.jip.2015.05.005. Epub 2015 May 21. Review.</citation>
    <PMID>26003824</PMID>
  </reference>
  <reference>
    <citation>Green TJ, Speck P. Antiviral Defense and Innate Immune Memory in the Oyster. Viruses. 2018 Mar 16;10(3). pii: E133. doi: 10.3390/v10030133. Review.</citation>
    <PMID>29547519</PMID>
  </reference>
  <reference>
    <citation>Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang QW, Xu SY, Zhu HD, Xu YC, Jin Q, Sharma L, Wang L, Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Jul 28;71(15):778-785. doi: 10.1093/cid/ciaa310.</citation>
    <PMID>32198501</PMID>
  </reference>
  <reference>
    <citation>Sousa H, Hinzmann M. Review: Antibacterial components of the Bivalve's immune system and the potential of freshwater bivalves as a source of new antibacterial compounds. Fish Shellfish Immunol. 2020 Mar;98:971-980. doi: 10.1016/j.fsi.2019.10.062. Epub 2019 Oct 30. Review.</citation>
    <PMID>31676427</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Porto</investigator_affiliation>
    <investigator_full_name>Jorge Pereira Machado</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

